Hana Securities announced on the 19th that microneedle pipeline development is going smoothly for Lapas. No investment opinion was provided.
Raphas is a microneedle patch developer and manufacturer established in 2006. As a company that developed its own ‘DEN ( Droplet Extension )스포츠토토‘ original manufacturing technology, it is developing a vaccine microneedle patch. Cho Jung-hyun, a researcher at Hana Securities , said, “We look forward to the commercialization of the pharmaceutical microneedle patch.” “The main
product is a microneedle patch for acne treatment . With the start of production ( ODM ), sales growth is expected to begin in earnest.” He continued, “As an additional pipeline , we are developing a nicotinamide-based microneedle patch for acne treatment . It is expected to be released in the US in the 4th quarter after the FDA ) inspection,” he added. Raphas specializes in rhinitis, diabetes/obesity, dementia,
Researcher Cho said, ” ‘RapMed-1506 (rhinitis)’ will be able to confirm the results of phase 1 clinical trials for safety and efficacy in patients with allergic rhinitis in the fourth quarter of this year.” “‘RapMed-2003 ( diabetes , Obesity)’ new drug is being jointly developed with Daewon Pharmaceutical, and we are aiming to apply for a phase 1 clinical trial ( IND ) within this year.”